Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients

Gun Min Kim, Young Sam Kim, Young Ae Kang, Jae Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Seung Taek Lim, Joo Hang Kim, Se Kyu Kim, Byoung Chul Cho

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin- derivative antitumor agent that belongsto the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safetyof belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). METHODS:: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS:: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%). CONCLUSION:: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.

Original languageEnglish
Pages (from-to)731-736
Number of pages6
JournalJournal of Thoracic Oncology
Volume7
Issue number4
DOIs
Publication statusPublished - 2012 Apr

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Kim, G. M., Kim, Y. S., Ae Kang, Y., Jeong, J. H., Kim, S. M., Hong, Y. K., Sung, J. H., Lim, S. T., Kim, J. H., Kim, S. K., & Cho, B. C. (2012). Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. Journal of Thoracic Oncology, 7(4), 731-736. https://doi.org/10.1097/JTO.0b013e31824b23cb